NIH Awards $67M in EUREKA Grants

-
The National Institutes of Health has granted $67.4 million in funding for trailblazing research that could reap great benefits but which are not guaranteeing immediate results, including genomics and proteomics studies, NIH said Monday.

The Exceptional, Unconventional Research Enabling Knowledge Acceleration (EUREKA) program grants $200,000 per year for up to four years for researchers that test unconventional ideas or "tackle major methodological or technical challenges," according to NIH. Of the 56 grants, 10 researchers will receive a total of $10.6 million for two-year awards through the American Recovery and Reinvestment Act of 2009.

"EUREKA awards reflect NIH's continued commitment to funding transformative research, even if it carries more than the usual degree of scientific risk," NIH Director Francis Collins said in a statement. "The grants seek to elicit those 'eureka moments' when scientists make major theoretical or technical advances."

"The research supported by EUREKA could provide us with new concepts, tools and approaches that have a profound impact on our understanding of biology — from fundamental life processes to human diseases and behavior," said Jeremy Berg, Director of the National Institute of General Medical Sciences, which led development of the program.

The grants include support for a study at Arizona State University, Tempe, titled "Working Backwards from the Proteome"; development for a genome-wide RNAi screening platform for the common lab at Scripps Research Institute; a study at the University of Miami of the genome, transcriptome, and proteome interaction in the human cortex, or the human 'brainome'; and a study of single-cell functional genomics at Yeshiva University, among others.

The EUREKA program was developed with collaboration from the National Cancer Institute, the National Institute on Aging, the National Institute of Mental Health, the National Institute on Drug Abuse, the National Institute on Neurological Disorders and Stroke, and the National Library of Medicine.

More information regarding the grants can be found here.



XTractor Premium - A Platform for discovery, knowledge sharing, analysis and modelling of published biomedical facts.









Comments

Post a Comment

Popular posts from this blog

Sequence Analysis is still sexy:Dual Descriptor Method for Biological Sequence Analysis

-
The emergence of “Systems Biology” in recent years highlights the systematic viewpoint of bio-system modeling. Building on such a background, Dual Descriptor Method, a generic methodology for biological sequence analysis is proposed. From a systematic perspective, Dual Descriptor is defined as a two element set of Composition Weight Map and Position Weight Function which aim at reflecting the composition and permutation information of a sequence. An alternate training algorithm is provided to get an optimum description of the building patterns of the sequences. In this paper , dual descriptor method has been applied to the analysis of two typical problems of molecular biology: gene identification and the prediction of protein function. Satisfactory and insightful results are achieved. Owing to the generality of this methodology, dual descriptor method has wide application perspective for many problems of pattern recognition, especially those involved in “Systems Biology”. Be a part of
Read more

Abbott Laboratories Buys Piramal Healthcare Limited Biz for $3.72B

-
Abbott May 21 announced a definitive agreement with Piramal Healthcare Limited to acquire full ownership of Piramal's Healthcare Solutions business (Domestic Formulations), a leader in the Indian branded generics market, for an up-front payment of $2.12 billion , plus $400 million annually for the next four years, giving Abbott the No. 1 position in the Indian pharmaceutical market. This further accelerates Abbott's emerging markets growth following the recent acquisition of Solvay Pharmaceuticals and announcements last week of Abbott's collaboration with Zydus Cadila as well as the creation of a new stand-alone Established Products Division to focus on expanding the global markets for its leading branded generics portfolio. "This strategic action will advance Abbott into the leading market position in India , one of the world's most attractive and rapidly growing markets," said Miles D. White , chairman and chief executive officer, Abbott. &quo
Read more

List of Cheminformatics Companies & Institutions

-
Accelrys ACD/Labs (Advanced Chemistry Development, Inc.) Afferent Systems Inc. Agilent Technologies Aureus Pharma Barnard Chemical Information Ltd. (John Barnard and Geoff Downs) SEE: digital chemistry Bio-Rad Laboratories BioReason BioSolveIT BlueObelisk.org Bruker Daltonics Inc. Cambridge Crystallographic Data Centre CambridgeSoft Corporation CARB Center for Advanced Research in Biotechnology (NIST/University of Maryland) Cengent Therapeutics (Genes to Leads). Acquired by Inncardio, Inc. Center for Molecular Modeling (NIH) Centre for Molecular and Biomolecular Informatics CMBI (formerly: CAOS/CAMM: Dutch National Center for Computer-Assisted Chemistry and Molecular Modelling) Cerep ChemAxon ChemDiv, Inc. (Chemical Diversity) Chemical Abstracts Service Chemical Computing Group, Inc. Chemical Simulations Group ChemInnovation Software ChemNavigator ChemSW (Chemistry Software for Windows, formerly: WindowChem) Chenomx Inc. CIS Chemical Information System CombiChem.net CompuChem C
Read more